Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis tr

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA)

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra

Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue mov

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight a

Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Ph

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 mil

- ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243. 6 million, representing ~55% year-over

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra

Despite a volatile market, AOUT, CMPR, NESR, CTO and KNSA are five stocks showing recent price stren

If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pha

Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove

Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to m

Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for

Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-averag

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf

Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and risin

KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipelin

On June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing

If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pha

TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 20

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove

Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raise

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $900.000 million-$920.000 mil

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.27 per share which beat the

Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf

Kiniksa Pharmaceuticals (NASDAQ:KNSA) sees FY2026 sales of $900.000 million-$920.000 million vs $902

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.17 per share which missed th